Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy

Core Insights - Cidara Therapeutics, Inc. has made significant progress with its long-lasting flu prophylactic candidate, CD388, as indicated by positive Phase 2b trial results [1] Company Summary - Cidara Therapeutics is a biotechnology company based in San Diego, focusing on innovative treatments [1] - The company has received a "Buy" rating since February 2025, reflecting confidence in its product pipeline [1] Industry Context - The advancements in flu prophylactics, particularly with CD388, highlight the ongoing innovation within the biotech sector, especially in preventive treatments [1]